Levetiracetam in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register

Neurology

Volumn 67, Issue 10, 2006, Pages 1876-1879

  Hunt, S ^a   Craig, J ^a   Russell, A ^b   Guthrie, E ^c   Parsons, L ^d   Robertson, I ^e   Waddell, R ^a   Irwin, B ^a   Morrison, P J ^f,g   Morrow, J ^a  

^a ROYAL GROUP OF HOSPITALS   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c St Albans City Hospital ^*

^d St Albans City Hospital   (United Kingdom)

^e LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^g UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONGENITAL MALFORMATION; DISEASE REGISTRY; DRUG SAFETY; EPILEPSY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED KINGDOM; UTERUS;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTICONVULSANTS; BODY WEIGHT; EPILEPSY; FEMALE; GREAT BRITAIN; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; PIRACETAM; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; REGISTRIES;

EID: 33845405448     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000244491.48937.55     Document Type: Article

References (10)

1. Olafsson E, Hallgrimsson JT, Hauser WA, Ludvigsson P, Gudmundsson G. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998;39:887-892.
2. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-1138.
3. Kaneko S, Battino D, Andermann R, et al. Congenital malformations due to anti-epileptic drugs. Epilepsy Res 1999;33:145-158.
4. Samren EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-746.
5. Cunnington M, Tennis P, et al. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005;64:955-960.
6. Isoherranen N, Spiegelstein O, Bialer M, et al. Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity. Epilepsia 2003;44:1280-1288.
7. Long L. Levetiracetam monotherapy during pregnancy: a case series. Epilepsy Behav 2003;4:447-448.
8. ten Berg K, Samren EB, van Oppen AC, Engelsman M, Lindhout D. Levetiracetam use and pregnancy outcome. Reprod Toxicol 2005;20:175-178.
9. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198.
10. McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med 1999;340:1234-1238.